In a report published Tuesday, Credit Suisse analyst Glen Santangelo reiterated an Outperform rating on Catamaran CTRX, and raised the price target from $61.00 to $64.00.
In the report, Credit Suisse noted, “[Last] evening after the market close, CTRX announced it had signed a 10-year strategic PBM partnership with Cigna. This deal provides a significant reputational boost for CTRX & removes a major overhang on the shares, while providing some incremental EPS accretion. We agree with the after-market spike in the shares (+14%), and would expect the shares nearterm to trend back to the recent all-time high level ($57-58).”
Catamaran closed on Monday at $48.66.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.